BridgeBio Pharma Stock Forecast

Stock Price Forecast

According to 23 analysts polled by S&P Global, BridgeBio Pharma stock has a consensus rating of "Strong Buy" and an average price target of $104.25. The average 1-year stock price forecast is 26.12% higher than the current stock price, while the lowest is $80 (-3.22%) and the highest is $157 (+89.93%).

Price Target: $104.25 (+26.12%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$80	$104.25	$100.5	$157
Change	-3.22%	+26.12%	+21.58%	+89.93%

Analyst Ratings

The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	15	16	16	15	16	15
Buy	5	5	6	6	6	6
Hold	1	1	1	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	21	22	23	23	24	23

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates $110 → $120	Buy	Reiterates	$110 → $120	+45.17%	Jul 13, 2026
Jason Zemansky Bank of America Securities	Bank of America Securities	Buy Maintains $101	Buy	Maintains	$101	+22.19%	Jul 9, 2026
Biren Amin Piper Sandler	Piper Sandler	Buy Maintains $111	Buy	Maintains	$111	+34.29%	Jul 9, 2026
Eliana Merle Barclays	Barclays	Buy Reiterates $157	Buy	Reiterates	$157	+89.93%	Jul 8, 2026
Luca Issi RBC Capital	RBC Capital	Buy Maintains $100	Buy	Maintains	$100	+20.98%	Jul 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

967.01M

from 502.08M

92.60%

from 502.08M

Revenue Next Year

1.61B

from 967.01M

66.43%

from 967.01M

EPS This Year

-2.15

from -3.78

EPS Next Year

0.56

from -2.15

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	69.72M	77.65M	9.30M	221.90M	502.08M	967.01M
Revenue Growth	745.15%	11.38%	-88.02%	2,285.27%	126.26%	92.60%
Gross Profit	66.60M	74.21M	6.86M	218.02M	481.11M	899.65M
Gross Margin	95.53%	95.58%	73.71%	98.25%	95.82%	93.03%
Operating Income	-573.33M	-468.44M	-599.44M	-577.37M	-502.06M	-304.70M
Net Income	-562.54M	-481.18M	-643.20M	-535.76M	-724.93M	-439.92M
EPS	-	-	-	-	-3.78	-2.15
Free Cash Flow	-301.13M	-285.88M	-240.16M	-291.12M	-325.29M	-271.47M
No. Analysts	-	-	-	-	-	21

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	1.1B
Avg	967.0M
Low	844.4M

Revenue Growth

Revenue Growth	2026	2027	2028
High	120.2%
Avg	92.6%
Low	68.2%

EPS Forecast

EPS	2026	2027	2028
High	-1.49
Avg	-2.15
Low	-2.62

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-